Government advisers have recommended that people should use a prescription version of fish oil to deal with health issues. Presently, the drug Vascepa got accepted for use in a relatively small group of patients. It is suggested to those people who have very high levels of triglycerides, fats in the blood that are connected to heart disease. The drugmaker Amarin wants the Food and Drug Administration to allow Vascepa for other issues that are related to heart health. Doctors may suggest the drug to patients with lower fat levels, but who are still at risk of heart issues and who take medications for high cholesterol. A group of advisors to the Food and Drug Administration, of FDA, all accepted to support the propagation based on a recent study result. The study disclosed that the drug could decrease rates of life-threatening heart issues in high-risk patients.
Doctor Jack Yanovski is a member of the advisory group, and a hormone specialist from the National Institutes of Health has stated that there is no doubt this drug could be beneficial for a large number of people. The advisory group noted various side effects of the drug. They also included an unbalanced heartbeat and bleeding inside the body. But the members accepted the good results outweighed those risks when a patient is a doctor’s supervision. The FDA is not needed to follow the advice of the group. The authority is hoped to decide by the end of this year. One member of the advisory group urged that drug labeling should target patients who need it.
A new label would make Vascepa the first fat-burning drug by the FDA to decrease heart issues. The advisory group based its decision on a study that was clinched by the manufacturer. The study found that Vascepa reduced the risk of heart attack, blocked arteries, and other issues by about 25% compared to a passive treatment. Millions of Americans take fish oil supplements that they believe improve their health. Fish oils are rich in omega-3 fatty acids that reduce triglycerides. But some studies have failed to display that this directly has good results on patients.
